Search

Your search keyword '"Doebele, Robert C."' showing total 745 results

Search Constraints

Start Over You searched for: Author "Doebele, Robert C." Remove constraint Author: "Doebele, Robert C."
745 results on '"Doebele, Robert C."'

Search Results

51. Data from Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

52. Supplementary Figures 1 - 5 from An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

53. Supplementary Figure 2 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

54. Supplementary Figure 1 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

55. Supplementary Figure 4 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

56. Figure S4 from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms

57. Supplementary Data from Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

58. Supplementary Methods and Figure Legends from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

59. Supplementary Table 1 from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms

61. Data from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms

62. Data from An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

63. Supplementary Figure 3 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

64. Supplementary Data from A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

66. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

70. Supplementary Figures 1,2, 3 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

71. Supplementary Figures 1-5 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

72. Supplementary Figure 2 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

73. Supplementary Figures 1-5, Tables 1-2 from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

74. Data from Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

75. Supplementary Figures S1-S10. from Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

78. Supplementary Tables 1-2 from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases

79. Supplementary Figure Legends 1-5 from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

80. Supplementary Table 2 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

81. Supplementary Table 3 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

82. Data from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

83. Supplementary Table 1 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

84. Figures S1-9 and Legends from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases

85. Supplementary Table 2 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

87. Supplementary Figure Legends 1-3 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

88. Supplementary Figure 1 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

89. Supplementary Figure 3 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

90. Supplementary Table 4 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

91. Supplementary Table 1 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

92. Table 1 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

93. Supplementary Table 3 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

94. Data from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases

95. Abstract P5-02-07: Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis

97. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression

98. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

99. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

Catalog

Books, media, physical & digital resources